Steven Hull
Pulmonary Disease · Lees Summit, MONPI 1366435919
Payments from drug & device makers
What this record shows
That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$10,085,513in research payments, 2019–2025
Across 53 payments — averaging $190,293 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$5.2M
- Takeda Pharmaceuticals U.S.A., Inc.$4.3M
- Amgen$574K
How this compares
$0 in reported general payments places this provider in the 0th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Lees Summit
- Quintin CokingtinLees Summit$17K
- Sidney DevinsLees Summit$11K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.